Wedbush Upgrades Arcus Biosciences Ahead of Key 2026 Clinical Data

Wedbush upgraded Arcus Biosciences with a new $41 price target and added the stock to its Best Ideas List ahead of major 2026 clinical updates for casdatifan in kidney cancer.